Quectel announces packed program of products and demos at KES 2023
SEOUL, South Korea--(BUSINESS WIRE)--Korean Electronics Show, Seoul: Quectel Wireless Solutions, a global IoT solutions provider,…
3 years ago
Alex
Smartsheet Invests in Australia-based Data Hosting to Better Serve Global Customer Base
The enterprise work management leader’s newest regional deployment will provide customers the ability to host…
3 years ago
Fabrinet to Announce First Quarter Fiscal Year 2024 Financial Results on November 6, 2023
BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical…
3 years ago
Gold Resource Corporation Announces Q3 2023 Conference Call
DENVER--(BUSINESS WIRE)--Gold Resource Corporation (NYSE American: GORO) (the “Companyâ€) will host a conference call Friday,…
3 years ago
Polaris and OrionVM Partner to Next-Gen Cloud Transform Queensland ICT Market
OrionVM’s MicroPoP Technology Enables Leading Australian Data Centre to Uniquely Underpin Cloud Workloads, Including Enterprise…
3 years ago
New Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV Market
Westwater Resources Offers Domestic Alternatives CENTENNIAL, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE: American: WWR), an energy…
3 years ago
Nanban Ventures Sends Letter Highlighting Steps Being Taken to Protect Investors
DALLAS--(BUSINESS WIRE)--Nanban Ventures LLC (“Nanban Venturesâ€), a Dallas-based venture capital firm investing in startups and…
3 years ago
Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd. (“Avistone†or “the Companyâ€), a clinical-stage biotechnology company focused on…
3 years ago
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median…
3 years ago
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by…
3 years ago